Quoc-Dien Trinh, MD, MPH

Explore the latest advancements in metastatic hormone-sensitive prostate cancer treatment, highlighting effective agents and clinical trial outcomes.

Explore the critical underrepresentation of black men in metastatic hormone sensitive prostate cancer trials and its implications for treatment outcomes.

A panelist discusses how the differences in prostate cancer among Black men are multifactorial, including biological differences in risk alleles, social determinants of health, and limited access to care and clinical trials.

A panelist discusses how Black men have a 67% higher incidence of prostate cancer and more than 2-fold higher risk of mortality compared with members of other races and ethnicities.